Therapy-induced regressive changes of prostate cancer;Therapieinduzierte tumorregression des prostatakarzinoms

Pathologe

Volumn 25, Issue 6, 2004, Pages 461-468

  Helpap, B ^a   Kollermann J ^b  

^a Hegau Klinikum   (Germany)

^b KLINIKUM FULDA   (Germany)

Author keywords

Androgen deprivation; Histology; Prostate cancer; Radiation therapy; Regressive changes

Indexed keywords

ANTIANDROGEN;

ARTICLE; BASAL CELL; CANCER REGRESSION; CELL DESTRUCTION; CELL HYPERPLASIA; CELL ISOLATION; CELL VACUOLE; CYTOPLASM; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVOLUTION; MORPHOLOGY; PROSTATE CANCER; STROMA; TUMOR CELL;

ANDROGEN ANTAGONISTS; CELL NUCLEUS; HUMANS; MALE; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STROMAL CELLS;

EID: 11144304053     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-004-0708-3     Document Type: Article

References (30)

1. Armas OA, Aprikian AG, Melamed J et al. (1994) Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18:979-991
2. Bazinet M, Zheng W, Begin LR et al. (1997) Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49:721-725
3. Bostwick DG, Ramnani D, Cheng L (1999) Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Urol Clin North Am 26:465-479
4. Carroll PR, Kantoff PW, Balk SP et al. (2003) Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60 (Suppl 1):1-6
5. Cheng L, Cheville JC, Pisansky TM et al. (1999) Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol 23:803-808
6. Cheng L, Lloyd RV, Weaver AL et al. (2000) The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6:1896-1899
7. Civantos F, Marcial MA, Banks ER et al. (1995) Pathology of androgen deprivation therapy in prostate carcinoma. Cancer 75:1634-1641
8. Cookson MS, Sogani PC, Russo P et al. (1997) Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 79:432-438
9. Debruyne FMJ, Witjes WPJ (2000) Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol Urol 4:251-256
10. Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3582-3593
11. Ferguson J, Zincke H, Ellinson E et al. (1994) Decrease of prostativ intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44:91-95
12. Gleave ME, La Bianca SE, Goldenberg SL et al. (2000) Long term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5 year follow-up. Urology 56:289-294
13. Gomella LG, Zeltser I, Valicenti RK (2003) Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 62 (Suppl 1):46-54
14. Helpap B (2002) Fundamentals on the pathology of prostatic carcinoma after brachytherapy. World J Urol 20:207-212
15. Helpap B, Bocking A, Dhom G et al. (1985) Classification, histologic and cytologic grading and regression grading of prostate cancer. Urologe A 24:156-159
16. Helpap B, Koch V (1991) Histological and immunohistochemical findings of prostatic carcinoma after external or interstitial radiotherapy. J Cancer Res Clin Oncol 117:608-614
17. Hussain M, Smith DC, El-Rayes BF et al. (2003) Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61:774-780
18. Köllermann J, Caprano J, Budde A et al. (2003) Follow-up of nondetectable prostate carcinoma (pTO) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology 62:476-80
19. Köllermann J, Feek U, Müller H et al. (2000) Nondected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 38:714-720
20. Köllermann J, Helpap B (2001) Neuroendocrine differentiation and short term neoadjuvant hormonal treatment of prostatic carcinoma with special regard to tumor regression. Eur Urol 40:313-317
21. Köllermann J, Hopfenmüller W, Caprano J et al. (2004) Prognosis of stage pT0 after prolonged neo-adjuvant endocrine therapy of prostate cancer: a matched-pair analysis. Eur Urol 45:42-45
22. Köllermann JW (1995) Das Prostatakarzinom im Stadium C: Das Verhalten des Malignitäts- und Regressionsgrades unter induktiver Therapie. Inauguraldissertation, Johannes Gutenberg Universität Mainz
23. Montironi R, Magi Galluzi C, Muzzonigro G et al. (1994) Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 47:906-913
24. Montironi R, Magi Galluzi C, Fabris G (1995) Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 191:873-880
25. Murphy WM, Soloway MS, Barrows GH (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68:821-828
26. Reuter VE (1997) Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (Suppl 3A):16-22
27. Smith DM, Murphy WM (1994) Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73:1472-1477
28. Tran T, Jennings TA, Ross JS, Nazeer T (1998) Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma. A distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am J Surg Pathol 22:347-354
29. Vaillancourt L, Tetu B, Fradet Y et al. (1996) Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomised study. Am J Surg Pathol 20:86-93
30. Zhou M, Shah R, Shen R et al. (2003) Basal cell cocktail (34βE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 27:365-371